Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich lowered its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 91.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,084 shares of the biotechnology company’s stock after selling 23,201 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Arcturus Therapeutics were worth $39,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 846 shares in the last quarter. SG Americas Securities LLC grew its position in Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after buying an additional 3,705 shares in the last quarter. Spire Wealth Management grew its position in Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 10,746 shares in the last quarter. BNP Paribas Financial Markets grew its position in Arcturus Therapeutics by 954.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,831 shares of the biotechnology company’s stock valued at $367,000 after buying an additional 14,330 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in Arcturus Therapeutics in the 3rd quarter valued at about $420,000. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Trading Down 7.6 %

ARCT stock opened at $13.21 on Wednesday. Arcturus Therapeutics Holdings Inc. has a one year low of $12.75 and a one year high of $45.00. The firm has a market capitalization of $357.82 million, a PE ratio of -5.95 and a beta of 2.96. The firm has a 50-day moving average of $16.83 and a two-hundred day moving average of $18.44.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million for the quarter, compared to analysts’ expectations of $44.64 million. On average, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ARCT shares. Canaccord Genuity Group decreased their target price on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. HC Wainwright reduced their price objective on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Finally, Wells Fargo & Company reduced their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $59.20.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.